奥泰生物 (688606)
Hangzhou Alltest Biotech Co., Ltd.
K-Line Chart
No K-line data available
Company NameHangzhou AllTest Biotech Co., Ltd.
Listing Date2021-03-25
Issue Price133.67RMB
Registered Capital7928.085510k RMB
Legal RepresentativeGao Fei
Registered AddressBuildings 3, 4, 5, No. 550 Yinhai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Jianggan District, Hangzhou City, Zhejiang Province, China.
IndustryMedical Devices
Main BusinessResearch, development, production, and sales of in vitro diagnostic reagents.
Company ProfileHangzhou AllTest Biotech Co., Ltd. is engaged in the research, development, and production of in vitro diagnostic reagents. The company has passed the ISO13485:2003 quality management system certification by TÜV Europe, and multiple products have obtained CE registration in Europe. Its leading products are rapid diagnostic products, covering five major series including Women's Health, Infectious Diseases, Drugs of Abuse, Oncology, and Cardiovascular, which are sold in over 100 countries and regions worldwide. Currently, the company holds 3 patents. It possesses strong R&D and technological innovation capabilities, maintaining a leading domestic position in advanced biological fields such as labeling technologies (colloidal gold, latex, etc.), biological raw material technologies (monoclonal antibodies, polyclonal antibodies, recombinant antigens, synthetic antigens), and immunochromatographic technology.
Stock Details
1. Key Indicators
- Total Shares(W): 7928.09
- Circulating A-Shares(W): 7928.09
- Earnings Per Share(RMB): 2.3900
- Net Assets Per Share(RMB): 49.2146
- Operating Revenue(W RMB): 63307.66
- Total Profit(W RMB): 21824.60
- **Net Profit Attributable to Parent(W RMB) **: 18980.97
- Net Profit Growth Rate(%): -3.91
- Weighted Return on Equity(%): 4.8500
- Operating Cash Flow Per Share(RMB): 1.4440
- Undistributed Profit Per Share(RMB): 24.0376
- Capital Reserve Per Share(RMB): 21.3997
2. Main Business
The main business covers:
- Research, development, production, and sales of in vitro diagnostic reagents
3. Company Basic Information
- Company Name: Hangzhou AllTest Biotech Co., Ltd.
- Listing Date: 2021-03-25
- Industry: Pharmaceutical Manufacturing
- Address: No. 550, Yin Hai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Jianggan District, Hangzhou City, Zhejiang Province
- Website: https://www.alltests.com.cn
- Company Profile: The issuer was established as a joint stock company through the overall transformation of AllTest Limited. On October 19, 2017, AllTest Limited held a shareholders' meeting where all shareholders unanimously agreed to act as promoters. Using July 31, 2017, as the restructuring reference date, and based on the audited net asset value of the company of RMB 122,411,449.07 (as per the audit report Zhong Hui Hui Shen [2017] No. 4842 from Zhonghui Accounting Firm (Special General Partnership)), the company was converted into a joint stock company at a ratio of 3.13956:1, resulting in a share capital of 38.99 million shares (par value RMB 1 per share). The registered capital was RMB 38.99 million, and the balance of the net assets after deducting the share capital, RMB 83,421,449.07, was recorded as capital reserve. On October 19, 2017, Tianyuan Asset Appraisal Co., Ltd. issued an Asset Appraisal Report (Tianyuan Ping Bao Zi [2017] No. 0400), appraising the company's overall value as RMB 133.3939 million as of July 31, 2017, which exceeded the company's audited net asset value. On October 19, 2017, all promoters of AllTest Biotech signed the "Sponsor Agreement for the Establishment of Hangzhou AllTest Biotech Co., Ltd.". On November 8, 2017, Zhonghui Accounting Firm (Special General Partnership) issued a Capital Verification Report (Zhong Hui Hui Yan [2017] No. 4843), verifying that the registered capital of the joint stock company, contributed through the net assets of the limited company during the overall restructuring, had been fully paid up as of November 8, 2017. On November 8, 2017, all promoters of AllTest Biotech legally convened the inaugural meeting and the first shareholders' meeting of the joint stock company, adopted the company's articles of association, and elected the directors for the first board of directors and the non-employee representative supervisors for the first board of supervisors. On November 29, 2017, AllTest Biotech obtained the Business License (Unified Social Credit Code: 91330101685842840Y) issued by the Hangzhou Market Supervision Administration.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hangzhou Jingguan Investment Management Co., Ltd. | General Legal Person | 1849.26 | 23.33 |
| 2 | Hangzhou Qunze Investment Management Co., Ltd. | General Legal Person | 1502.20 | 18.95 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 218.73 | 2.76 |
| 4 | Hangzhou Saida Investment Partnership (Limited Partnership) | General Legal Person | 209.29 | 2.64 |
| 5 | GTJA Polaris Value Advantage Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 71.33 | 0.90 |
| 6 | Ningbo Weny Venture Capital Partnership (General Partnership) | General Legal Person | 70.23 | 0.89 |
| 7 | Penghua Hongjia Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 44.95 | 0.57 |
| 8 | Penghua Anqing Hybrid Securities Investment Fund Class A | Fund | 6.28 | 0.08 |
| 9 | Penghua Anhe Hybrid Securities Investment Fund Class A | Fund | 5.54 | 0.07 |
| 10 | Penghua Zunhui 18-month Regular Open Hybrid Securities Investment Fund Class A | Fund | 4.39 | 0.06 |
5. Concept Sectors
- Gene Concept
- Helicobacter Pylori
- Assisted Reproduction
- Hepatitis Concept
- Pet Economy
- Margin Trading & Securities Lending
- Blue-chip Stocks
- Below IPO Price
- Overseas Business
- CSI Dividend
- STAR 200
- SSE 580
Remarks
- Data update date: 2025-11-01
- Data source: Public Market Information